AbbVie Q3 2026 earnings include $216 million bought IPR&D and milestones expense
ABBV•AbbVie said its Q3 2026 GAAP and adjusted earnings include $216 million in bought IPR&D and milestones expense, reducing adjusted diluted EPS by $0.11. Its adjusted diluted EPS guidance is $3.73-$3.77 for Q3 and $13.76-$13.96 for full-year 2026.
1. Earnings and guidance
A SEC filing said AbbVie's Q3 2026 GAAP and adjusted earnings include $216 million in bought in-process research and development and milestones expense, with a $0.11 impact on Q3 GAAP and adjusted diluted EPS. AbbVie's adjusted diluted EPS guidance, including bought IPR&D, is $3.73-$3.77 for Q3 and $13.76-$13.96 for full-year 2026.
